NextCure (NXTC) EBITDA Margin (2019 - 2020)
NextCure (NXTC) posted EBITDA Margin of -168.97% for FY2020, up 379.04 percentage points from -548.01% in FY2019.
Analysis
NextCure (NXTC) EBITDA Margin (2019 - 2020) Analysis & Trends
- Business Quant data shows NXTC's EBITDA Margin at -548.01% in FY2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 42.49% |
| 10 | NextCure | 29.30 Mn | -71.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 40.05% |
| Dec 31, 2019 | -560.75% |
| Sep 30, 2019 | -563.11% |
| Jun 30, 2019 | -597.22% |
| Mar 31, 2019 | -460.72% |
API Access
NextCure EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NXTC&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "NXTC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=NXTC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();